Market Summary
USD61.10-1.07
Market Closed-1.72%
BRKR Stock Price
BRKR RSI Chart
BRKR Valuation
BRKR Price/Sales (Trailing)
BRKR Profitability
BRKR Fundamentals
BRKR Revenue
BRKR Earnings
Price Action
52 Week Range
52.2284.84
(Low)(High)
Last 7 days
-0.4%
Last 30 days
-7.3%
Last 90 days
-16.6%
Trailing 12 Months
12.4%
BRKR Financial Health
BRKR Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for BRKR
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-11 | Munch Mark | sold (taxes) | -105,663 | 66.96 | -1,578 | exec vp&pres bruker nano inc. |
2023-08-11 | Herman Gerald N | sold (taxes) | -61,134 | 66.96 | -913 | executive vice president, cfo |
2023-08-11 | LAUKIEN FRANK H | sold (taxes) | -296,030 | 66.96 | -4,421 | president & ceo |
2023-08-10 | Srega Juergen | acquired | - | - | 14,695 | president calid |
2023-08-10 | Busse Falko | acquired | - | - | 4,526 | president, biospin group |
2023-08-10 | Prause Burkhard | acquired | - | - | 2,371 | pres. & ceo, bruker best |
2023-08-10 | Munch Mark | acquired | - | - | 12,410 | exec vp&pres bruker nano inc. |
2023-08-10 | Herman Gerald N | acquired | - | - | 12,168 | executive vice president, cfo |
2023-08-10 | LAUKIEN FRANK H | acquired | - | - | 38,521 | president & ceo |
2023-08-09 | Munch Mark | sold (taxes) | -140,621 | 65.68 | -2,141 | exec vp&pres bruker nano inc. |
Which funds bought or sold BRKR recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | reduced | -59.56 | -9,535,360 | 5,824,010 | 0.02% |
2023-09-20 | BARCLAYS PLC | added | 228 | 3,367,000 | 4,988,000 | -% |
2023-09-12 | Farther Finance Advisors, LLC | added | 90.37 | 11,576 | 26,325 | 0.01% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | unchanged | - | -334 | 5,027 | -% |
2023-09-05 | Covenant Partners, LLC | new | - | 275,204 | 275,204 | 0.10% |
2023-09-01 | Portside Wealth Group, LLC | new | - | 296,198 | 296,198 | 0.06% |
2023-08-22 | COMERICA BANK | new | - | 10,000 | 10,000 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -35.6 | -1,009,000 | 1,537,540 | 0.01% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 10.43 | 44,000 | 1,298,000 | 0.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -3.49 | -979,755 | 9,315,250 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Bruker
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | t. rowe price investment management, inc. | 11.1% | 16,368,144 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 7.51% | 11,045,016 | SC 13G/A | |
| Feb 08, 2023 | massachusetts financial services co /ma/ | 5.1% | 7,513,039 | SC 13G | |
| Jan 31, 2023 | blackrock inc. | 7.6% | 11,118,621 | SC 13G/A | |
| Jan 23, 2023 | laukien joerg c | 5.1% | 7,515,769 | SC 13G | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 13.7% | 20,854,627 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 7.10% | 10,765,626 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 04, 2022 | blackrock inc. | 7.2% | 10,844,554 | SC 13G |
Recent SEC filings of Bruker
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Oct 03, 2023 | 3 | Insider Trading | |
| Oct 03, 2023 | 4 | Insider Trading | |
| Sep 29, 2023 | SC TO-T/A | SC TO-T/A | |
| Sep 20, 2023 | SC TO-T/A | SC TO-T/A | |
| Aug 31, 2023 | SC TO-T | SC TO-T | |
| Aug 17, 2023 | SC TO-C | SC TO-C | |
| Aug 14, 2023 | 4 | Insider Trading | |
| Aug 14, 2023 | 4 | Insider Trading | |
| Aug 14, 2023 | 4 | Insider Trading | |
| Aug 14, 2023 | 4 | Insider Trading |
Peers (Alternatives to Bruker)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
TMO | 192.8B | 43.5B | -10.34% | -4.46% | 33.68 | 4.43 | 1.64% | -23.14% |
A | 32.3B | 7.0B | -9.56% | -12.76% | 28.51 | 4.62 | 5.03% | -14.68% |
MTD | 23.5B | 4.0B | -11.99% | -5.07% | 26.47 | 5.95 | 2.30% | 16.37% |
ILMN | 21.2B | 4.5B | -20.50% | -28.48% | -5.05 | 4.74 | -4.92% | -21931.58% |
BRKR | 9.0B | 2.7B | -7.34% | 12.40% | 28.11 | 3.3 | 9.64% | 16.50% |
| MID-CAP | ||||||||
NEO | 1.5B | 551.6M | -23.10% | 33.93% | -12.93 | 2.69 | 12.73% | 21.90% |
| SMALL-CAP | ||||||||
PACB | 2.0B | 146.1M | -31.29% | 34.48% | -6.15 | 13.44 | 4.72% | -55.19% |
QTRX | 1.0B | 112.0M | -0.85% | 155.15% | -15.26 | 8.97 | 0.83% | 16.42% |
ADPT | 755.0M | 189.6M | -23.35% | -28.00% | -3.95 | 3.98 | 18.74% | 17.75% |
EYPT | 275.5M | 37.3M | -23.67% | 12.62% | -2.6 | 7.38 | -9.96% | -38.49% |
HBIO | 182.7M | 114.1M | -2.95% | 61.51% | -33.65 | 1.6 | -5.49% | -48.58% |
CDXS | 138.9M | 99.2M | 10.56% | -67.22% | -2.45 | 1.4 | -26.56% | -199.52% |
CDXC | 107.8M | 80.9M | -7.69% | 9.09% | -16.6 | 1.33 | 17.20% | 77.07% |
BNGO | 95.4M | 31.5M | -25.45% | 59.44% | -0.65 | 3.03 | 35.12% | -38.47% |
Bruker News
Returns for BRKR
Cumulative Returns on BRKR
11.7%
10-Year Cumulative Returns
15.9%
7-Year Cumulative Returns
13.2%
5-Year Cumulative Returns
16.5%
3-Year Cumulative Returns
Risks for BRKR
What is the probability of a big loss on BRKR?
73.5%
Probability that Bruker stock will be more than 20% underwater in next one year
37.7%
Probability that Bruker stock will be more than 30% underwater in next one year.
5.4%
Probability that Bruker stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BRKR drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Bruker was unfortunately bought at previous high price.
Drawdowns
Financials for Bruker
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 3.6% | 2,715 | 2,621 | 2,531 | 2,506 | 2,476 | 2,458 | 2,418 | 2,362 | 2,264 | 2,118 | 1,988 | 1,960 | 1,970 | 2,035 | 2,073 | 2,026 | 1,972 | 1,925 | 1,896 | 1,873 | 1,842 |
| Cost Of Revenue | 4.1% | 1,313 | 1,262 | 1,225 | 1,224 | 1,221 | 1,221 | 1,208 | 1,181 | 1,144 | 1,092 | 1,048 | 1,037 | 1,041 | 1,062 | 1,077 | 1,055 | 1,031 | 1,010 | 996 | 989 | 982 |
| Gross Profit | 3.1% | 1,401 | 1,359 | 1,306 | 1,281 | 1,255 | 1,237 | 1,210 | 1,181 | 1,121 | 1,026 | 940 | 923 | 929 | 973 | 995 | 972 | 941 | 915 | 900 | 883 | 860 |
| Operating Expenses | 3.3% | 930 | 900 | 873 | 854 | 846 | 817 | 796 | 780 | 752 | 705 | 692 | 670 | 669 | 698 | 694 | 682 | 670 | 649 | 638 | 632 | 626 |
| S&GA Expenses | 4.1% | 650 | 624 | 607 | 596 | 593 | 575 | 561 | 538 | 512 | 479 | 469 | 469 | 479 | 501 | 500 | 487 | 468 | 455 | 445 | 439 | 436 |
| R&D Expenses | 4.6% | 260 | 248 | 236 | 231 | 226 | 223 | 221 | 220 | 216 | 204 | 198 | 188 | 185 | 190 | 188 | 186 | 182 | 177 | 173 | 172 | 171 |
| EBITDA | -100.0% | - | 543 | 527 | 500 | 480 | 505 | 497 | - | - | 396 | 321 | 324 | 331 | 347 | 372 | 356 | 335 | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.21* | 0.21* | 0.20* | 0.19* | 0.21* | 0.21* | - | - | 0.19* | 0.16* | 0.17* | 0.17* | 0.17* | 0.18* | 0.18* | 0.17* | - | - | - | - |
| Interest Expenses | - | - | - | 24.00 | - | - | - | 20.00 | - | - | - | 29.00 | - | - | - | 16.00 | - | - | - | 12.00 | - | - |
| Earnings Before Taxes | 1.9% | 434 | 427 | 414 | 412 | 392 | 402 | 394 | 380 | 346 | 298 | 226 | 231 | 239 | 256 | 280 | 269 | 252 | 247 | 245 | 233 | 215 |
| EBT Margin | -100.0% | - | 0.16* | 0.16* | 0.16* | 0.16* | 0.16* | 0.16* | 0.16* | 0.15* | 0.14* | 0.11* | 0.12* | 0.12* | 0.13* | 0.14* | - | - | - | - | - | - |
| Net Income | 2.4% | 319 | 312 | 297 | 275 | 274 | 282 | 277 | 270 | 238 | 204 | 158 | 158 | 165 | 177 | 197 | 207 | 189 | 184 | 180 | 98.00 | 92.00 |
| Net Income Margin | -100.0% | - | 0.12* | 0.12* | 0.11* | 0.11* | 0.11* | 0.11* | 0.11* | 0.10* | 0.10* | 0.08* | 0.08* | 0.08* | 0.09* | 0.10* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 149 | 145 | 119 | 114 | 176 | 190 | 254 | 312 | 304 | 235 | 169 | 140 | 141 | 140 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 2.5% | 3,857 | 3,764 | 3,612 | 3,337 | 3,385 | 3,551 | 3,650 | 3,128 | 3,087 | 3,035 | 3,049 | 2,879 | 2,943 | 2,962 | 2,772 | 2,352 | 2,350 | 2,243 | 2,129 | 1,889 | 1,806 |
| Current Assets | 2.4% | 2,183 | 2,133 | 2,113 | 2,037 | 2,088 | 2,251 | 2,472 | 1,989 | 1,968 | 1,946 | 1,925 | 1,826 | 1,957 | 1,990 | 1,796 | 1,434 | 1,406 | 1,344 | 1,304 | 1,262 | 1,182 |
| Cash Equivalents | -3.9% | 575 | 598 | 646 | 626 | 726 | 820 | 1,072 | 577 | 612 | 700 | 686 | 571 | 750 | 799 | 682 | 300 | 287 | 303 | 326 | 275 | 263 |
| Inventory | 6.5% | 915 | 859 | 800 | 750 | 759 | 740 | 710 | 733 | 730 | 701 | 692 | 696 | 665 | 626 | 577 | 587 | 595 | 542 | 510 | 519 | 509 |
| Net PPE | 2.3% | 523 | 511 | 487 | 422 | 395 | 404 | 406 | 389 | 398 | 384 | 396 | 355 | 336 | 319 | 306 | 278 | 282 | 268 | 271 | 261 | 259 |
| Goodwill | 5.8% | 558 | 527 | 458 | 382 | 396 | 384 | 340 | 324 | 315 | 313 | 320 | 313 | 295 | 290 | 293 | 282 | 285 | 6.00 | 276 | 200 | 8.00 |
| Current Liabilities | 0.2% | 1,051 | 1,049 | 914 | 865 | 818 | 881 | 939 | 921 | 955 | 944 | 792 | 683 | 750 | 766 | 646 | 643 | 641 | 633 | 599 | 563 | 532 |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 332 | 323 | 225 | 206 |
| LT Debt, Non Current | 1.2% | 1,123 | 1,109 | 1,201 | 1,137 | 1,171 | 1,205 | 1,222 | 718 | 721 | 716 | 842 | 828 | 924 | 915 | 813 | 519 | 494 | - | 323 | - | - |
| Shareholder's Equity | 2.7% | 1,231 | 1,199 | 1,114 | 937 | 984 | 1,031 | 1,085 | 1,090 | 1,015 | 982 | 974 | 963 | 907 | 925 | 917 | 855 | 870 | 922 | 905 | 817 | 777 |
| Retained Earnings | - | - | - | 1,926 | - | - | - | 1,660 | - | - | - | 1,407 | - | - | - | 1,275 | - | - | - | 1,103 | - | - |
| Additional Paid-In Capital | - | - | - | 256 | - | - | - | 238 | - | - | - | 216 | - | - | - | 200 | - | - | - | 177 | - | - |
| Shares Outstanding | 0.0% | 147 | 147 | 147 | 147 | 148 | 149 | 151 | 152 | 151 | 152 | 152 | 153 | 154 | 154 | 154 | 154 | 156 | 157 | 157 | 156 | 156 |
| Minority Interest | 5.4% | 20.00 | 19.00 | 12.00 | 11.00 | 14.00 | 14.00 | 14.00 | 14.00 | 13.00 | 14.00 | 13.00 | 11.00 | 9.00 | 9.00 | 10.00 | 10.00 | 9.00 | 8.00 | 9.00 | 8.00 | 9.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 20.2% | 342 | 284 | 274 | 242 | 196 | 262 | 282 | 347 | 405 | 395 | 332 | 265 | 235 | 234 | 213 | 210 | 185 | 210 | 240 | 211 | 219 |
| Share Based Compensation | -15.6% | 22.00 | 26.00 | 28.00 | 28.00 | 27.00 | 21.00 | 17.00 | 17.00 | 17.00 | 17.00 | 16.00 | 10.00 | 10.00 | 10.00 | 10.00 | 13.00 | 13.00 | 12.00 | 11.00 | 11.00 | 11.00 |
| Cashflow From Investing | -32.2% | -341 | -258 | -251 | -150 | -141 | -270 | -192 | -172 | -172 | -116 | -192 | -203 | -167 | -232 | -158 | -275 | -292 | -258 | -123 | 77.00 | 154 |
| Cashflow From Financing | 30.4% | -159 | -228 | -415 | 25.00 | 105 | 139 | 319 | -159 | -382 | -391 | -161 | 191 | 397 | 500 | 300 | 99.00 | 133 | 78.00 | -112 | -278 | -332 |
| Dividend Payments | -0.7% | 30.00 | 30.00 | 30.00 | 28.00 | 27.00 | 26.00 | 24.00 | 24.00 | 24.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | - | - |
| Buy Backs | -33.2% | 121 | 181 | 263 | 321 | 248 | 226 | 153 | 140 | 145 | 157 | 123 | 73.00 | 123 | - | 142 | 285 | 400 | - | - | - | - |
BRKR Income Statement
2023-06-30UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Total revenue | $ 681.9 | $ 588.4 | $ 1,367.2 | $ 1,183.4 |
| Total cost of revenue | 341.4 | 290.2 | 667.0 | 578.9 |
| Gross profit | 340.5 | 298.2 | 700.2 | 604.5 |
| Operating expenses: | ||||
| Selling, general and administrative | 177.9 | 152.2 | 340.6 | 297.9 |
| Research and development | 71.0 | 59.6 | 140.0 | 116.2 |
| Other charges, net | 5.4 | 12.5 | 10.7 | 20.0 |
| Total operating expenses | 254.3 | 224.3 | 491.3 | 434.1 |
| Operating income | 86.2 | 73.9 | 208.9 | 170.4 |
| Interest and other income (expense), net | (8.7) | (4.3) | (24.8) | (6.8) |
| Income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries | 77.5 | 69.6 | 184.1 | 163.6 |
| Income tax provision | 19.9 | 19.9 | 49.8 | 51.8 |
| Equity in income of unconsolidated investees, net of tax | 0.2 | 0.0 | 0.9 | 0.0 |
| Consolidated net income | 57.8 | 49.7 | 135.2 | 111.8 |
| Net income attributable to noncontrolling interests in consolidated subsidiaries | 0.7 | 0.2 | 1.6 | 0.7 |
| Net income attributable to Bruker Corporation | $ 57.1 | $ 49.5 | $ 133.6 | $ 111.1 |
| Net income per common share attributable to Bruker Corporation shareholders: | ||||
| Basic | $ 0.39 | $ 0.33 | $ 0.91 | $ 0.74 |
| Diluted | $ 0.39 | $ 0.33 | $ 0.91 | $ 0.74 |
| Weighted average common shares outstanding: | ||||
| Basic | 146.8 | 149 | 146.8 | 149.7 |
| Diluted | 147.7 | 149.8 | 147.6 | 150.6 |
| Comprehensive income | $ 52.9 | $ 15.9 | $ 145.5 | $ 69.1 |
| Less: Comprehensive income (loss) attributable to noncontrolling interests | 1.3 | (0.4) | 2.6 | (0.2) |
| Less: Comprehensive loss attributable to redeemable noncontrolling interest | (0.3) | (0.5) | (0.3) | (0.7) |
| Comprehensive income attributable to Bruker Corporation | 51.9 | 16.8 | 143.2 | 70.0 |
| Product | ||||
| Total revenue | 559.6 | 485.8 | 1,126.7 | 976.2 |
| Total cost of revenue | 272.8 | 230.1 | 530.0 | 459.1 |
| Other | ||||
| Total revenue | 122.3 | 102.6 | 240.5 | 207.2 |
| Total cost of revenue | $ 68.6 | $ 60.1 | $ 137.0 | $ 119.8 |
BRKR Balance Sheet
2023-06-30UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 574.8 | $ 645.5 |
| Accounts receivable, net | 450.8 | 472.7 |
| Inventories | 914.6 | 800.1 |
| Assets held for sale | 0.0 | 1.4 |
| Other current assets | 243.1 | 193.5 |
| Total current assets | 2,183.3 | 2,113.2 |
| Property, plant and equipment, net | 522.7 | 487.0 |
| Goodwill | 557.9 | 457.6 |
| Intangible assets, net | 300.4 | 270.9 |
| Other long-term assets | 292.7 | 283.1 |
| Total assets | 3,857.0 | 3,611.8 |
| Current liabilities: | ||
| Current portion of long-term debt | 120.9 | 18.7 |
| Accounts payable | 188.8 | 178.4 |
| Deferred revenue and customer advances | 397.4 | 370.2 |
| Other current liabilities | 343.8 | 347.0 |
| Total current liabilities | 1,050.9 | 914.3 |
| Long-term debt | 1,122.5 | 1,200.5 |
| Other long-term liabilities | 421.0 | 365.2 |
| Commitments and contingencies (Note 16) | ||
| Redeemable noncontrolling interests | 11.9 | 6.1 |
| Shareholders' equity: | ||
| Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding | 0.0 | 0.0 |
| Common stock, $0.01 par value 260,000,000 shares authorized, 175,498,835 and 175,389,586 shares issued and 146,817,075 and 147,023,144 shares outstanding at June 30, 2023 and December 31, 2022, respectively | 1.7 | 1.7 |
| Treasury stock, at cost, 28,681,760 and 28,366,442 shares at June 30, 2023 and December 31, 2022, respectively | (1,107.2) | (1,085.0) |
| Accumulated other comprehensive income, net of tax | 24.4 | 14.8 |
| Other shareholders' equity | 2,312.3 | 2,182.3 |
| Total shareholders' equity attributable to Bruker Corporation | 1,231.2 | 1,113.8 |
| Noncontrolling interests in consolidated subsidiaries | 19.5 | 11.9 |
| Total shareholders' equity | 1,250.7 | 1,125.7 |
| Total liabilities, redeemable noncontrolling interests and shareholders' equity | $ 3,857.0 | $ 3,611.8 |
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.